About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNANCT05198128

Ovarian Hyperstimulation Syndrome Using Calcium Infusion

the incidence of OHSS and clinical outcomes after calcium IV infusion in high-risk women undergoing ART

Lead sponsor: Al-Azhar University•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Al-Azhar University

Among assisted reproductive technologies (ART), ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic complication affects up to 30% of women undergoing ART and caries high risks of morbidity and mortality. Women with age younger than 35 years, those with history of polycystic ovary syndrome (PCOS), or having a history of previous OHSS are more susceptible to develop OHSS

Age

18 - 45 years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•\- infertile women aged 20 to 38 years. BMI ranged from 18 to 40. serum FSH within normal limits( 1-12IU /l) presented with ovarian response suggestive of being at risk of developing OHSS because of the presence of at least 15 follicles of 10 mm or greater on the day of hCG administration.

Exclusion Criteria

•endocrinopathies. a systemic disease. and Insulin-dependent diabetes Thyroid disease using any medication (e.g., insulin-sensitizing drugs and GnRH antagonists. patients need coasting for high risk of OHSS. patients need cycle cancellation. severe male infertility requiring testicular sperm extraction.

Related studies

Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement Therapy

NCT05588635 · Ovarian Hyperstimulation Syndrome, Frozen-thawed Embryo Transfers

Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders

NCT04797338 · Pregnancy Early, Miscarriage, and more

COMPLETEDPhase 2

Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response

NCT04351126 · Ovarian Hyperstimulation Syndrome

TERMINATEDPhase 4

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

NCT01606709 · Endometrial Receptivity, Ovarian Hyperstimulation Syndrome

COMPLETEDPhase 4

Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS

NCT01815138 · Ovarian Hyperstimulation Syndrome

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 22, 2022Terms

Trial snapshot

StatusUNKNOWN

PhaseNA

Enrollment200

Start dateMar 2022

Last updatedFeb 22, 2022

Condition

Ovarian Hyperstimulation Syndrome

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 22, 2022Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions